Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanxi Dayu Biological Functions Co's earnings before interest and taxes (EBIT) for the
three
months ended in Jun. 2026 was ¥-7.7 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was ¥-42.8 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Shanxi Dayu Biological Functions Co's annualizedROC % for the quarter that ended in Jun. 2026 was -3.94%.
Shanxi Dayu Biological Functions Co's annualizedROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -8.90%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Shanxi Dayu Biological Functions Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -4.92%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanxi Dayu Biological Functions Co EBIT Related Terms
Shanxi Dayu Biological Functions Co EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Shanxi Dayu Biological Functions Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanxi Dayu Biological Functions Co EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanxi Dayu Biological Functions Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Shanxi Dayu Biological Functions Co's EV-to-EBIT falls into.
Shanxi Dayu Biological Functions Co EBIT Calculation
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-42.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanxi Dayu Biological Functions Co (BJSE:920970) has a EBIT of ¥-42.8 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shanxi Dayu Biological Functions Co.
Is Shanxi Dayu Biological Functions Co's EBIT too high?
Shanxi Dayu Biological Functions Co's current EBIT is ¥-42.8 Mil. Overall, Shanxi Dayu Biological Functions Co has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanxi Dayu Biological Functions Co's EBIT compare to VRTX and REGN?
Shanxi Dayu Biological Functions Co's EBIT of ¥-42.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shanxi Dayu Biological Functions Co. Shanxi Dayu Biological Functions Co's current EBIT is ¥-42.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanxi Dayu Biological Functions Co stock overvalued right now?
Based on GuruFocus' analysis, Shanxi Dayu Biological Functions Co (BJSE:920970) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥7.30, compared to a current price of ¥6.58 — trading 9.9% below its estimated fair value. The current EBIT is ¥-42.8 Mil. Shanxi Dayu Biological Functions Co's overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Shanxi Dayu Biological Functions Co (BJSE:920970), the current EBIT is ¥-42.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanxi Dayu Biological Functions Co (BJSE:920970) Overvalued in 2026?
Based on GuruFocus' analysis, Shanxi Dayu Biological Functions Co stock appears to be undervalued.
The current stock price of ¥6.58 is trading 9.9% below its estimated GF Value™ of ¥7.30.
GuruFocus considers Shanxi Dayu Biological Functions Co to be Modestly Undervalued.
Key valuation signals for BJSE:920970:
EBIT: ¥-42.8 Mil
GF Value™: ¥7.30 vs. price of ¥6.58 (9.9% below fair value)
No single metric tells the full story. See the BJSE:920970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanxi Dayu Biological Functions Co Ltd engages in the research and development of bioengineering technology and product application. Its main products are probiotics, enzyme preparations, fermented traditional Chinese medicine, biological preparations, and veterinary preparations.
66GF Score
Get the complete analysis for BJSE:920970
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920970 has been successfully added to your 
